Market Overview

Wells Fargo Analyst Michael Ton Says Valeant May Have to Raise Offer for Obagi or Walk Away

Related VRX
Benzinga's Option Alert Recap From February 24
Exclusive: Clinical-Stage Specialty Pharma EyeGate CEO On Relationship With Valeant
Wells' Maris bearish on Valeant, sees as much as 39% downside risk (Seeking Alpha)

In a note from Wells Fargo analyst Michael Ton, concern is being raised over the current $19.75 per share offer from Valeant Pharmaceuticals (NYSE: VRX) for Obagi (NASDAQ: OMPI).

Concerns come from a recent offer by Merz Pharma, which may force Valeant to raise its offer, cut into margins or abandon the acquisition all together.

Tong went on to note that Valeant has a history of walking away from competitive bidding.

Following the news, Valeant Pharma traded roughly flat, while Obagi traded up 16.24 percent to $22.91.

Latest Ratings for VRX

Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Rodman & RenshawDowngradesBuyNeutral

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color News M&A Analyst Ratings


Related Articles (OMPI + VRX)

View Comments and Join the Discussion!